Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 8.3% in September

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 2,490,000 shares, a growth of 8.3% from the September 15th total of 2,300,000 shares. Based on an average daily trading volume, of 423,800 shares, the days-to-cover ratio is presently 5.9 days. Currently, 2.9% of the company’s stock are sold short.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in CMPX. Bleakley Financial Group LLC acquired a new position in Compass Therapeutics during the 1st quarter valued at approximately $80,000. Vanguard Group Inc. lifted its stake in Compass Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after buying an additional 71,008 shares during the last quarter. CM Management LLC boosted its holdings in shares of Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after acquiring an additional 185,000 shares during the period. Opaleye Management Inc. bought a new position in shares of Compass Therapeutics during the first quarter worth about $6,277,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after acquiring an additional 31,433 shares during the period. 68.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

CMPX has been the subject of several research analyst reports. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, August 12th.

Compass Therapeutics Stock Down 3.8 %

CMPX stock traded down $0.07 during trading on Thursday, hitting $1.91. 2,218,530 shares of the company’s stock traded hands, compared to its average volume of 432,007. The stock has a market capitalization of $262.11 million, a price-to-earnings ratio of -5.29 and a beta of 0.90. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.34. The stock has a fifty day moving average price of $1.57 and a two-hundred day moving average price of $1.40.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). The business had revenue of $0.85 million during the quarter. As a group, equities research analysts expect that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.